LINC01281: A Potential Drug Target for EIF4F-Related Diseases

Target Name: LINC01281

NCBI ID: G286442

LINC01281

Other Name(s): Long intergenic non-protein coding RNA 1281 | long intergenic non-protein coding RNA 1281

LINC01281: A Potential Drug Target for EIF4F-Related Diseases

LINC01281 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is located within the long non-coding RNA (lnc) domain and is characterized by its ability to interact with various proteins, including the protein encoded by the gene EIF4F.

The EIF4F protein is a key regulator of the cell cycle and has been implicated in a number of cellular processes, including cell division, apoptosis, and autophagy. It is also known to play a role in the development and progression of various diseases, including cancer.

Research has suggested that LINC01281 may interact with EIF4F and that this interaction may be important for the regulation of cellular processes. In addition, studies have shown that LINC01281 is expressed in a variety of tissues and that it is highly stable in the cell.

These findings suggest that LINC01281 may be a promising drug target or biomarker for the study of EIF4F-related diseases. Further research is needed to confirm these findings and to determine the full extent of LINC01281's potential role in these fields.

Protein Name: Long Intergenic Non-protein Coding RNA 1281

The "LINC01281 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01281 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets